skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A (Code C92586)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A

Definition: A recombinant form of the human PRAME (Preferentially Expressed Antigen of Melanoma) protein combined with the AS15 adjuvant, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, GSK2302025A may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the PRAME protein, resulting in tumor cell lysis. The tumor-associated antigen PRAME is often overexpressed by a variety of tumor cell types. AS15 is an potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid, and QS-21.

Label: Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A

NCI Thesaurus Code: C92586 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL421638  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A

External Source Codes: 
PDQ Closed Trial Search ID 681046
PDQ Open Trial Search ID 681046 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C92586
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom